A prospective, randomized phase III trial comparing combination chemotherapy with cyclophosphamide, doxorubicin, and 5-fluorouracil with vinorelbine plus doxorubicin in the treatment of advanced breast carcinoma

Reporting results of cancer treatment

1981 • 7,916 citations

Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer.

1996 • 754 citations

Phase II trial of weekly intravenous vinorelbine in first-line advanced breast cancer chemotherapy.

1993 • 333 citations

Intravenous vinorelbine as first-line and second-line therapy in advanced breast cancer.

1995 • 196 citations

Vinorelbine as first-line chemotherapy for metastatic breast carcinoma.

1994 • 191 citations

A prospective randomized phase III trial comparing combination chemotherapy with cyclophosphamide, fluorouracil, and either doxorubicin or epirubicin. French Epirubicin Study Group.

1988 • 176 citations

Phase III randomized study of fluorouracil, epirubicin, and cyclophosphamide v fluorouracil, doxorubicin, and cyclophosphamide in advanced breast cancer: an Italian multicentre trial. Italian Multicentre Breast Study with Epirubicin.

1988 • 167 citations

Phase-II study of Navelbine in advanced breast cancer.

1989 • 132 citations

The synthesis of Navelbine prototype of a new series of vinblastine derivatives.

1989 • 112 citations

Phase II trial of weekly IV vinorelbine in first-line advanced breast cancer chemotherapy

1994 • 110 citations

Vinorelbine: an overview

1996 • 108 citations

Phase II trial of vinorelbine/doxorubicin as first-line therapy of advanced breast cancer.

1994 • 102 citations

Phase II Trial of Weekly IV Vinorelbine as a Single Agent in First-Line Advanced Breast Cancer Chemotherapy

1995 • 78 citations

A phase II, multicentre, UK study of vinorelbine in advanced breast cancer

1994 • 72 citations

Factors predicting for response, time to treatment failure, and survival in women with metastatic breast cancer treated with DAVTH: a prospective Eastern Cooperative Oncology Group study.

1991 • 72 citations

Management of breast cancer patients failing adjuvant chemotherapy with adriamycin-containing regimens

1981 • 67 citations

Response to secondary therapy in patients with adenocarcinoma of the breast previously treated with adjuvant chemotherapy

1983 • 24 citations

Navelbine (NVB) and Doxorubicin (DX) both at 25 mg/m2, on days 1 & 8 for the management of advanced breast cancer (ABC)

1997 • 1 citations